Clinical Application of Next Generation Sequencing for Personalized Medicine in Solid Tumors
Presented by: Ryan Bender, PhD FACMG
Cancer Statistics
New driver mutations in non-small-cell lung cancerWilliam Pao, Nicolas Girard, Lancet Oncol 2011; 12: 175–80
• Mutations associated with drug sensitivityEGFR Gly719X, exon 19 deletion, Leu858Arg, Leu861Gln
• Mutations associated with primary drug resistanceEGFR exon 20 insertions
• Mutations associated with acquired drug resistanceEGFR Thr790Met, Asp761Tyr, Leu747Ser, Thr854Ala
• Traditionally, non-small-cell lung cancers have been classified according to histological features.
• Various driver mutations have been associated with these cancers over time.
• The mutations are mutually exclusive, except for those in PIK3CA.
Evolution of Knowledge in NSCLC
Lung Genetic Profiles Today (by Histology)
5
Next-Generation SequencingGreater volume of clinically-actionable information • Additional markers analyzed • Pathways more fully interrogated • Clinical trials opportunities expanded
Additional service and reporting options • Expanded NGS panel for Select and Comprehensive profiles • 45 gene pan-tumor NGS panel
Enhanced specimen-friendly requirements • Smaller specimens accepted (8-10 unstained, unbaked, positively charged slides) • FFPE or Formalin samples accepted
6
Illumina MiSeq
©2013 Caris Life Sciences and affiliates.
7
Illumina MiSeq TruSeq Amplicon Cancer Hotspot Panel Validation
• Used 80 FFPE samples (70 FFPE tissue samples, 6 cell lines and 4 HapMap samples)
• >98% accuracy when compared to Sanger. • One discordant result stemming from misalignment of
A502_Y503dup mutation in KIT (Using Pindel and validating bioinformatics solution)
• >97% precision for inter-operator, inter-lot and inter-machine tests (Most sources of discordance involved indeterminate results)
• Linear and reliable variant detection down to 5%• All reported mutations have >99% confidence at a sensitivity of
10%©2013 Caris Life Sciences and affiliates.
8
NGS Use in Pathway Analysis For Personalized Medicine
©2013 Caris Life Sciences and affiliates.
Current Biomarkers for Colorectal Cancer
10
Anti-EGFR Monoclonal Antibodies
©2012 Caris Life Sciences, Ltd. and Affiliates
• Cetuximab (Erbitux)– Manufactured and marketed by ImClone and Bristol-Myers
Squibb (~$30,000/ 8 week cycle)– Approved in 2006 for treatment of squamous cell
carcinomas of the head and neck • Panitumamab (Vectibix)– Manufactured by Amgen (~$100,000/year)– Approved for treatment of colorectal cancer in 2006
• 2009 – Discovered KRAS mutations are negative indicators of response to EGFR mabs in colorectal cancer
11
The EGFR Pathway and Colon Cancer
©2012 Caris Life Sciences, Ltd. and Affiliates
12
The “Real” EGFR Pathway
©2012 Caris Life Sciences, Ltd. and Affiliates
13
The EGFR Pathway and Colon Cancer
©2012 Caris Life Sciences, Ltd. and Affiliates
14
Benefit of Molecular Profiling on Therapy Response
©2013 Caris Life Sciences and affiliates.Adapted from DeRooke et al. 2010
15
Current Commercial and Caris Offerings
Gene ASR Commercial Kits Current NGS Offering
KRAS 7 most frequent mutations affecting codons 12 and 13
All mutations at codons 12, 13 and 61 as well as additional mutations (A146T)
BRAF V600E/K All V600 mutations as well as mutations in exon 11 and other mutations near V600 (D594, L597 and K601)
PIK3CA E542K, E545K, E545D and H1047R
All mutations in exons 9 and 20 as well as select mutations in exons 1, 5 and 7
NRAS None All codon 12, 13 and 61 mutations
PTEN None Protein expression by IHC and hotspot mutation analysis
©2012 Caris Life Sciences, Ltd. and Affiliates
16
NGS as a Companion to Companion Diagnostics
©2013 Caris Life Sciences and affiliates.
17
Roche cobas BRAF Mutation Assay• FDA approved companion
diagnostic for Zelboraf use• Specific to the p.V600E
mutation• Can pick up other
mutations – p.V600K, p.V600D, p.V600E(2), V600_K601delinsD
• Does not detect p.V600R
©2012 Caris Life Sciences, Ltd. and Affiliates
18
BRAF Mutation Analysis• Sequencing
– V600E– Other V600 mutations– Exon 15 insertions/deletions (V600_K601delinsE/D)– L597 and K601 mutations– Exon 11 mutations
• FDA Approved Method – BRAF cobas 4800 V600 mutation test– PCR based– FDA approved companion diagnostic for Zelboraf and Debrafenib
©2012 Caris Life Sciences, Ltd. and Affiliates
19
BRAF Mutation Analysis: PCR vs Sequencing
©2012 Caris Life Sciences, Ltd. and Affiliates
Sample PCR Result Sequencing Result
Patient 1 Wild Type V600E(2)
Patient 2 Mutated V600K
Patient 3 Wild Type V600K
Patient 4 Wild Type V600R
Patient 5 Mutated Wild Type
V600E
04/19/2023 20
Detection of BRAF V600E(2) by NGS
04/19/2023 21
Detection of BRAF V600E(2) by NGS
22
Cobas BRAF Mutation Assay
23©2012 Caris Life Sciences, Ltd. and Affiliates
24
NGS and Incidental Findings
©2013 Caris Life Sciences and affiliates.
25
Case #1• 64 y/o patient presenting with growth on spinal cord• Biopsy reveal heavily pigmented nodule positive for MART-1,
HMB-45 and MITF• Malignant melanoma with unknown primary favored as Dx• Sample tested for standard melanoma markers• NGS performed with a request to report BRAF and KIT
mutation status• GNA11 Q209L mutation detected
©2013 Caris Life Sciences and affiliates.
04/19/2023 26
Case #1 H&E
27©2013 Caris Life Sciences and affiliates.
04/19/2023 28
Melanoma vs Melanocytoma
Melanocytoma Melanoma
Metastatic Not typical Typical
5-yr Survival ~80% complete resection~40% incomplete resection
Stage II – 45-80%Stage IV – 5-20%
Typical Therapy Surgical resection and/or radiation
Surgical resection and/or chemotherapy
Typical Mutated Oncogenes
GNAQ and GNA11 BRAF, NRAS and KIT
Targeted Therapies None Currently Available –MEK inhibitor trials
Vemurafenib, Imatinib, Sunitinib
29
Conclusions• NGS sequencing is a high throughput method for
interrogation of the mutation status of a large number of biomarkers
• Pathway analysis is expensive and laborious by previous methods – becoming standard of care for cancer therapy
• NGS adds additional information that some companion diagnostics do not provide
• Potential benefit of incidental findings to clarify diagnosis or detect rare finding
©2013 Caris Life Sciences and affiliates.
04/19/2023 30
Questions?